Myelodysplasia (MDS) is often thought of as “pre-leukemia.” Which is kind of misleading, because only some cases of MDS go on to become leukemia; others stay the same and never progress.
In MDS, there is some sort of abnormality in a myeloid stem cell. If you look at the cells in the blood and bone marrow, you’ll see dysmyelopoiesis (the red cells, neutrophils and/or megakaryocytes look abnormal). The neutrophils in the blood often show dysgranulopoiesis (they lack specific granulation) or hypolobulation (there are only a couple segments to the nucleus – or sometimes no segments at all, just a single round nucleus). Check out the neutrophil in the photo above: the cytoplasm is almost clear (certainly not nice and fawn-pink like you’d expect for a segmented neutrophil), and the nucleus doesn’t have nice segments – just a couple poorly-defined lobes.
In addition to the dysmyelopoietic changes, most cases show a macrocytic anemia. This is an important diagnostic feature, and an easy one to remember. If you see an older patient with a macrocytic anemia, MDS is something you should keep in mind (in addition to the more common causes of a macrocytic anemia, such as B12/folate deficiency and ethanol ingestion).
There may be an increase in myeloblasts in the blood or bone marrow – but if so, it’s a small increase (and certainly not more than 20%, which is the cutoff for acute myeloid leukemia).
There are actually a bunch of different kinds of MDS, everything from refractory anemia (which is just what it sounds like: anemia that does not respond to therapy such as B12 or iron) to chronic myelomonocytic leukemia in transformation (which is a bad name, actually, because it’s a type of MDS, not technically a leukemia). You should not try to memorize these subtypes unless you plan to take your hematopathology boards soon (or unless you have a particularly sadistic pathology professor).
The treatment depends on the type of MDS. Lower-grade types (like refractory anemia) rarely transform into acute leukemia, so they are treated more conservatively. Higher-grade types (like chronic myelomonocytic leukemia in transformation) may be treated more aggressively, particularly if they occur in a younger person who can handle chemotherapy well.
We need your help! Pathology Student is completely ad-free.If you find us useful, please consider donating whatever feels right to you. Every bit helps!You can donate here.
- Kristine said Hi Ayuba – The exact interaction between the antiphospholipid antibodies and the components of...
- Mosak said Am a vet student an dis xplaination really makes sense.kudos to you guyz
- ahmed said Thank you
- ahmed said Wonderful explanation
- ahmed said So nice explanation, you make pathology simple and comprehensive
- ahmed said Very useful lesson thank you very much,easily undrrstand
- Ayuba said Thanks for the explanation. Still want to know. Why are people with lupus antibodies present with th...
- fiona said thank you so much!
- Niloy said Alhamdulillah, i’v found answers at n8 b4 the exam…!
- Sahaja Parsa said What a thorough explanation! It makes me actually think about what those parameters ate as opposed t...
- HAMID IQBAL said It’s nice to get connected with Pathology community
- Kristine said Hi Maya – That’s a good question. When a lymphocyte is said to look “monocytoid...